Key result
Genomic profiling enables variant-targeted therapies in DCM despite challenges interpreting variants of unknown significance.
Why the study?
For treatments based on patient genotype to become feasible on a wider scale in dilated cardiomyopathy, obstacles such as interpreting variants of unknown significance need to be overcome.
No takes yet. Share an insight, caveat, or question.
May support precision medicine in dilated cardiomyopathy; leaves open confirmation in larger trials before practice change.
Fatkin et al. (2019) conducted a review in Dilated Cardiomyopathy. Precision medicine was evaluated. Precision medicine and genomic information offer opportunities for variant-targeted therapies in dilated cardiomyopathy, though interpreting variants of unknown significance remains a key challenge.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: